| |
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
Today’s Big NewsNov 18, 2024 |
|
Wednesday, December 4, 2024 | 11am ET / 8am PT Designing nanodevices that can change shape and function in response to molecular signals is a key objective in protein design, paving the way for the development of switchable nanomaterials, triggerable drug-delivery systems, and molecular motors. Join us for a deep dive into the recent progress in designing and characterizing a diverse range of switchable protein assemblies. Register now. 
|
|
| By Andrea Park Despite lingering barriers to equity, women continue to do incredible, groundbreaking work throughout pharma, biotech and medtech. As seen in the following profiles of 10 of the fiercest women in life sciences, they’re spearheading Big Pharma business development, guiding up-and-coming biotechs and leading clinical research into potentially lifesaving technologies and therapeutics. |
|
|
|
By Eric Sagonowsky The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters. |
By Angus Liu CSL Behring is shutting down its U.S. R&D hub for cell and gene therapy in Pasadena, California, Fierce Biotech has learned. |
By Ben Adams The new ulcerative colitis (UC) triumvirate in Johnson & Johnson’s Tremfya, AbbVie’s Skyrizi and Lilly’s Omvoh is rapidly growing into the established UC market as this IL-23 inhibitor class of drugs look to make its mark. |
|
Thursday, December 5, 2024 | 1pm ET / 10am PT Learn how to leverage comprehensive patient journeys to improve targeting, understand unmet needs, and optimize your competitive strategy with real-world evidence that sees what others can’t. Register now to gain a competitive edge by evolving beyond traditional, limited datasets and unlock a deeper understanding of patient and physician decision-making. 
|
|
By Conor Hale Developers from the University of Tokyo said the approach could lead to a non-contact screening method, as the conditions subtly alter blood flow in the face and hands. |
By Gabrielle Masson Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy in a phase 1/2 study. After discussions with the FDA, the biotech has launched a pivotal study and plans on filing for accelerated approval in 2026. |
By Kevin Dunleavy Just three days after Syndax Pharmaceuticals revealed data from a trial of revumenib in one indication of acute leukemia which chilled investors, the FDA has approved the small molecule in another indication of the disease. |
By Darren Incorvaia After failing to impress investors a year ago with an initial look at phase 2 data of a psilocybin-derived compound in major depressive disorder (MDD), Cybin momentarily boosted their spirits with a longer-term analysis. Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the Montgomery–Åsberg Depression Rating Scale. |
By Conor Hale When treating heart attack survivors, a study found that undergoing ablation before taking antiarrhythmic therapies may be the better option for people who have developed a dangerous heart rhythm. |
By Gabrielle Masson Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $745 million in biobucks for rights to a cancer candidate from Ratio Therapeutics. |
By Andrea Park Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re experiencing, potentially leading to less effective care. That’s according to a recent survey commissioned by AbbVie and comprising more than 400 U.S. adults with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. |
By Andrea Park AbbVie, the maker of three migraine treatment options, launched a contest this year to provide support for people whose migraines create obstacles in reaching their educational and career goals. |
By Fraiser Kansteiner Eisai has terminated a phase 3 study of lorcaserin as a potential adjunct treatment for patients with Dravet syndrome, a rare form of epilepsy that starts in infancy. The company is also shutting down an extended access program in which patients were able to access the medication off-label. |
By Nick Paul Taylor Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that has left a patient in critical condition. The discontinuation has pushed back the anticipated completion of enrollment in the low-dose cohort. |
By Fraiser Kansteiner Sanofi has unveiled a 40 million euro investment at its Lyon Gerland biomanufacturing site in France. The cash infusion will help bolster local production of the company’s polyclonal antibody Thymoglubulin for kidney transplant rejection, as well as expected future capacity needs for the type 1 diabetes drug Tzield. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we take a closer look at this year’s biotech graveyard, which tracks biotechs that have closed or are winding down. |
|
|---|
|
|
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now! 
|
|
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Unlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
